-methyladenosine (mA) is an abundant modification in mammalian mRNAs and plays important regulatory roles in gene expression, primarily mediated through specific recognition by "reader" proteins. YTH family proteins are one major family of known mA readers, which specifically recognize mA-modified transcripts the YTH domains. Despite the significant relevance of YTH-mA recognition in biology and diseases, few small molecule inhibitors are available for specifically perturbing this interaction. Here we report the discovery of a new inhibitor ("N-7") for YTH-mA RNA recognition, from the screening of a nucleoside analogue library against the YTH domain of the YTHDF1 protein. N-7 is characterized to be a -inhibitor against five YTH domains from human YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2 proteins, with IC values in the range of 30-48 μM measured using a fluorescence polarization competition assay. We demonstrated that N-7 directly interacts with the YTH domain proteins a thermal shift assay. N-7 expands the chemical structure landscape of the mA YTH domain-containing reader inhibitors and potentiates future inhibitor development for reader functional studies and therapeutic efforts in targeting the epitranscriptome.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353026PMC
http://dx.doi.org/10.1039/d4cb00105bDOI Listing

Publication Analysis

Top Keywords

discovery inhibitor
8
yth domain-containing
8
yth domains
8
yth domain
8
yth
7
inhibitor yth
4
domain-containing rna
4
rna readers
4
readers -methyladenosine
4
-methyladenosine abundant
4

Similar Publications

Discovery of noncovalent diaminopyrimidine-based Inhibitors for glioblastoma via a dual FAK/DNA targeting strategy.

Eur J Med Chem

January 2025

School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China. Electronic address:

Temozolomide, a widely used alkylating agent for glioblastoma treatment, faces significant challenges due to the development of resistance, which severely impacts patient survival. This underscores the urgent need for novel strategies to overcome this barrier. Focal adhesion kinase (FAK), an intracellular non-receptor tyrosine kinase, is highly expressed in glioblastoma cells and has been identified as a promising therapeutic target for anti-glioblastoma drug development.

View Article and Find Full Text PDF

Repurposing the familiar: Future treatment options against chronic kidney disease.

J Pharm Pharmacol

January 2025

Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, 333031, Rajasthan, India.

Objectives: Chronic kidney disease (CKD) is a serious health issue with rising morbidity and mortality rates. Despite advances in understanding its pathophysiology, effective therapeutic options are limited, necessitating innovative treatment approaches. Also, current frontline treatments that are available against CKD are not uniformly effective and often come with significant side effects.

View Article and Find Full Text PDF

Background: Anti-obesity medications are recommended for patients who do not achieve and maintain weight loss despite lifestyle interventions. S-309309 is a novel oral inhibitor of monoacylglycerol O-acyltransferase 2 being developed as a treatment for obesity.

Objective: The objective of the study was to investigate the safety, clinical pharmacology, pharmacokinetics and pharmacodynamic biomarker of S-309309.

View Article and Find Full Text PDF

ADC189 is a novel drug of cap-dependent endonuclease inhibitor. In our study, its antiviral efficacy was evaluated in vitro and in vivo, and compared with baloxavir marboxil and oseltamivir. A first-in-human phase I study in healthy volunteers included single ascending dose (SAD) and food effect (FE) parts.

View Article and Find Full Text PDF

Study on the absorption characteristics of euscaphic acid and tiliroside in fruits of Retz.

PeerJ

January 2025

Chinese University of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi, China.

The fruits of Retz. (FRL) have a long history of medicinal use, known for their rich composition of flavonoids, polyphenols, amino acids, sugars, and other bioactive compounds. FRL exhibits pharmacological effects such as antioxidant, antiviral, antibacterial, and antitumor activities, making it a valuable resource with significant development potential in both the food and pharmaceutical industries.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!